Suvratoxumab

A4DAB251 | Infectious diseases | Phase-III

Target Staphylococcus aureus Toxin A

Isotype / Subclass G1 / IgG1

Company

Biosynexus GlaxoSmithKline Regeneron Pharmaceuticals MedImmune

Clinical Status Phase-III

Format Whole mAb

Synonyms

AR-320 AR320 AR 320 MEDI-4893 MEDI4893 MEDI 4893

pH Formulation —

IMGT PubChem (374364067) PubChem (381127801) PubChem (404772611) PubChem (472405028) PubChem (496703331) PubChem (505056134) PubChem (505885993) Thera-SAbDab YAbS

Avg A4D Score

-0.7009

Score Range

-0.71 to -0.69

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB251_4u6v_K_M	4u6v	100%	-0.7106	6.5	4.0	-0.4409	-0.7444
A4DAB251_4u6v_H_L	4u6v	100%	-0.6913	6.5	4.0	-0.4103	-0.7265

Suvratoxumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2